



Neurocrine UK Limited (formerly Diurnal Limited)
Cardiff Medicentre
Heath Park
Cardiff
CF14 4UJ
United Kingdom
Tel: +44(0)29 20 682069

2024 Methodological Note – Diurnal Limited / Neurocrine UK Limited ‘Diurnal’ – Transfers of Value

Diurnal is part of the Neurocrine Biosciences group of companies and operates as a wholly owned subsidiary of Neurocrine Biosciences Inc. Diurnal changed its registered company name from Diurnal Limited to Neurocrine UK Limited, effective from 21 October 2024. Disclosures for the full year of 2024 are reported in the name of Diurnal, since this approach best enables full transparency for relevant payments made by the entity during that year. From 2025 onwards Disclosures will be reported in Diurnal’s new name of Neurocrine UK Limited. For the purposes of this note, ‘Diurnal’ shall mean the company Diurnal Limited, now known as Neurocrine UK Limited.

Diurnal is committed to adhering to the ABPI Code of Practice, ensuring all payments or other transfers of value made directly or indirectly to healthcare professionals (HCP), Other Relevant Decision Makers (ORDMs), and healthcare organisations (HCO) are documented and publicly disclosed.

This methodological note outlines the approach taken by Diurnal to ensure that the nature and scope of transfers of value (TOV) to HCPs, ORDMs and HCOs are clear and transparent to the public, and in accordance with the Association of the British Pharmaceutical Industry (ABPI) Code of Practice for the Pharmaceutical Industry.

Financial Data

Disclosure period: The disclosure report includes transfers of value occurring between 1 January 2024 – 31 December 2024.

Date methodology: The dates to be considered for disclosure reports are as follows:

- In Cash TOV: The payment date.
- In Kind TOV: Meeting or event end date.
- Benefit in kind donation: Start date.

Currency: Amounts are reported in UK sterling, where transfers of value were captured in other currencies, amounts were converted to UK sterling based on Neurocrine’s Finance Department Monthly Average Rates.

Value Added Tax (VAT): Where applicable, transfers of value declared include the VAT applied at relevant levels in countries in which the payment was made. Cross border TOV or indirect TOV may or may not include VAT depending on the submitting source or country.

Multi-year contracts: Where contracts are valid for more than one year, each individual TOV is captured and disclosed in the reportable disclosure period.

Cross Border Reporting: Diurnal includes TOV to covered recipients in the UK and other EFPIA countries. This includes all TOV made by any company in the Neurocrine Bioscience group to covered recipients in the European countries covered in the ABPI and EFPIA codes. Inclusion of covered recipients in other EFPIA countries goes beyond the requirements of the ABPI code. This decision aligns with the disclosure methodology previously implemented by Diurnal in 2023. Diurnal is unable to disclose values separately for regions outside the UK because it lacks affiliates and presence in certain markets.

Additionally, during 2024 Diurnal medicines were also marketed in other countries, for example the United States, Switzerland, Sweden, Denmark, Norway and Iceland by alliance partner pharmaceutical organisations who disclose TOV as separate entities.

Recipients: Payments made during 2024 to UK and European entities were reviewed, and direct and indirect transfers of value to covered recipients under the ABPI 2024 Code of Practice and EFPIA codes were identified, as categorized in the recipients definitions and Transfers of Value Categories below:

1. **Healthcare Professional (HCP):** A member of the medical, dental, pharmacy or nursing professions or any other person who, during his/her professional activities, may prescribe, purchase, supply, recommend or administer a Medicinal Product and whose primary practice, principal professional address or place of incorporation is in Europe.
2. **Other Relevant Decision Makers (ORDMs):** Includes recipients with an NHS role who could influence in any way the administration, consumption, prescription, purchase, recommendation, sale, supply or use of any medicine but who are not health professionals.
3. **Healthcare Organization (HCO):** Is defined as is a healthcare, medical or scientific association or organization such as a hospital, clinic, foundation, university or other teaching institution or learned society whose business address, place of incorporation or primary place of operation is in Europe or through which one or more HCPs provide services

Covered Recipient: Any reportable HCP, ORDM or HCO

Transfer of Value (TOV): A direct or indirect transfer of value, whether in cash, in kind or otherwise, in connection with the development or sale of medicines. A direct transfers of value is made directly by a company for the benefit of a recipient. Indirect transfers of value are those made on behalf of the company for the benefit of a Recipient, or those made through a Third Party and where Diurnal knows or can identify the Recipient that will benefit from the Transfer of Value.

Transfer of Value Categories

ABPI Transfer of Value Category	Example activities	HCP	HCO
<p>Donations and Grants (HCO Only): Provision of funds, benefits-in-kind or services freely given for the purpose of supporting healthcare, scientific research, or education with no consequent obligation on the recipient organisation, to provide goods or services to the benefit of Diurnal.</p>	<ul style="list-style-type: none"> Charitable contributions Business donations Educational grants (e.g. fellowships, courses provided by an HCO) 		YES
<p>Contributions to Cost of Event - Travel and accommodation relating to a congress or educational event: Payments covering travel, lodging, and related expenses for healthcare professionals attending meetings, conferences, or third-party educational/scientific meetings.</p>	<ul style="list-style-type: none"> Travel (e.g. flight, train, taxi, car hires, tolls, mileage reimbursement, parking) Accommodation 	YES	YES
<p>Contributions to Cost of Event - Registration fees: TOVs related to the registration of an HCP / HCO to attend a congress or educational event.</p>	<ul style="list-style-type: none"> Registration fees paid for the HCP/HCO to attend events 	YES	YES
<p>Sponsorship agreements: TOVs made to either the HCO directly or to an event organiser or other third party appointed by the HCO to manage an educational or scientific event.</p>	<ul style="list-style-type: none"> Congress sponsorship Stand or booth space Symposia 		YES
<p>Fees for Service: Payments made to HCPs or HCOs in return for providing services or consultancy work, such as speaking engagements, participation in advisory boards, or training delivery.</p>	<ul style="list-style-type: none"> Advisory board Speaker engagements or services Consultancy services 	YES	YES
<p>Related expenses to the fees for service contract: Any additional costs incurred by an HCP or HCO while providing a contracted service or consultancy work</p>	<ul style="list-style-type: none"> Travel (e.g. flight, train, taxi, car hire, tolls, mileage reimbursement, parking, shared ground transportation) Accommodation 	YES	YES
<p>Collaborative Working – which includes Joint Working: Engagement with other organizations in delivering initiatives which enhance patient care, for the benefit of patients or the National Health Service (NHS), to help with maintaining patient care.</p> <p><i>Note - Diurnal had no collaborative working agreements in 2024.</i></p>	<ul style="list-style-type: none"> Not Applicable 		YES

<p>Research and Development: This disclosure includes TOV to HCPs or HCOs related to the planning or conduct of:</p> <ul style="list-style-type: none"> • Non-clinical studies (as defined in OECD Principles on Good Laboratory Practice); or, • Clinical trials (as defined in Directive 2001/20/EC); or, • Non-interventional studies that are prospective in nature and that involve the collection of patient data from, or on behalf, of individual or groups of HCPs specifically for the study. 	<ul style="list-style-type: none"> • Clinical Trials • Data Monitoring Committees related to studies • Non-Interventional Studies that are prospective in nature • Investigators Initiated Research (IIR) • Clinical & Research Collaboration 	YES	YES
---	--	-----	-----

Data Protection

Consent Approach: Diurnal obtains the consent, as required, of each HCP to disclose their personal data primarily via data protection, privacy, and disclosure clauses in contracts. Diurnal will disclose the total value of the TOVs for those HCPs and ORDMs who have given consent for individual disclosure. For those who do not provide consent or where consent is withdrawn, their TOVs will be included in an aggregated total, as required by the ABPI Code.

Publication and Inquiries

Publication: Diurnal will publish transparency disclosure reports in line with the established timelines as defined by the ABPI.

Inquiries: Diurnal will review and investigate any inquiries from HCPs and HCOs concerning the submitted transparency reports. Any modifications resulting from this review will be incorporated into an updated report, in accordance with ABPI guidelines.